AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress ...

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types ...

Reform of special educational needs and disabilities (SEND) services must go hand in hand with the creation of a more ...

Since reading Andy Smith's terrific final blog as president last week, I’ve been pondering what to write in my first one with ...

Adcentrx's proprietary i-Conjugation® technology platform is an important component in the design of the company's ADCs. The platform utilizes protease-cleavable linkers and stable conjugation ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

Adcentrx to present new preclinical data at AACR 2025 on the company’s novel ADRX-0405 STEAP1 & ADRX-0134 NaPi2b ADCs. The company will deliver an oral presentation on ADRX-0405, its clinical ...